C4 Therapeutics Inc. (CCCC): Price and Financial Metrics
CCCC Price/Volume Stats
| Current price | $4.05 | 52-week high | $11.88 |
| Prev. close | $4.15 | 52-week low | $1.06 |
| Day low | $3.84 | Volume | 1,298,200 |
| Day high | $4.23 | Avg. volume | 2,113,993 |
| 50-day MA | $5.77 | Dividend yield | N/A |
| 200-day MA | $6.43 | Market Cap | 285.89M |
CCCC Stock Price Chart Interactive Chart >
C4 Therapeutics Inc. (CCCC) Company Bio
C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.
CCCC Price Returns
| 1-mo | -34.78% |
| 3-mo | -39.01% |
| 6-mo | -26.09% |
| 1-year | 166.45% |
| 3-year | -89.07% |
| 5-year | N/A |
| YTD | -28.32% |
| 2023 | -4.24% |
| 2022 | -81.68% |
| 2021 | -2.81% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...